<DOC>
	<DOCNO>NCT01658358</DOCNO>
	<brief_summary>Objectives : Phase I part - Primary Objective : To determine recommend dose combination lapatinib Lipo-Dox first line chemotherapy patient ErbB2 positive metastatic breast cancer . - Secondary Objectives : To define safety profile ; To observe response rate progression free survival Phase II part - Primary Objective : To determine objective response rate combination lapatinib Lipo-Dox first line chemotherapy patient ErbB2 positive metastatic breast cancer . - Secondary Objectives : To define safety profile ; To determine progression free survival</brief_summary>
	<brief_title>ErbB2 Positive Metastatic Breast Cancer</brief_title>
	<detailed_description>In phase I part Lapatinib ( L ) - dose level I , II 1000mg po daily dose level III , IV 1250mg po daily Intravenous Lipo Dox dose level reach day 1 21 day cycle• The recommended duration combination treatment patient least 8 cycle , , continue combination treatment cycle single lapatinib treatment ( start 1500 mg per day ) investigator 's discretion . The treatment stop progressive disease , unacceptable toxicity patient 's refusal occur . Intra patient escalation dose level allow major toxicity note . In phase II part Patients receive recommend dose accord phase I study result . The recommended duration combination treatment patient least 8 cycle , , continue combination treatment cycle single lapatinib treatment ( start 1500 mg per day ) investigator 's discretion . The treatment stop progressive disease , unacceptable toxicity patient 's refusal occur . Intra patient escalation dose level allow major toxicity note .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<criteria>Histologically confirm adenocarcinoma breast evidence metastatic disease Documented ErbB2 expression amplify disease invasive component primary metastatic lesion define : ErbB2 gene amplification FISH ( &gt; 6 ErbB2 gene copy per nucleus , FISH ratio ( ErbB2 gene copy chromosome 17 signal ) &gt; 2.2 ; Measurable disease , define ≥1 lesion accurately measure ≥1 dimension ≥20 mm conventional technique OR ≥10 mm spiral CT scan In phase II part , patient must chemonaïve metastatic setting . In phase I part , patient may receive prior chemotherapy metastatic setting . In phase I II part , prior Anthracyclines allow provide total dose doxorubicin hydrochloride ≤240 mg/m² epirubicin ≤ 600 mg/m² . At least 6 month since prior Anthracyclines , 6 week since prior Taxane . Patient must inform well understand current standard treatment , suggest first line treatment erbB2 positive , visceral organ metastatic breast cancer combination chemotherapy herceptin . In phase II part , patient must expose anterbB2 targeted therapy treatment metastatic setting . Herceptin treatment neoadjuvant adjuvant setting permit provide least 12 month elapse since last dose herceptin therapy . In phase I part , patient may receive prior antierbB2 target treatment metastatic setting . Hormone receptor menopausal status specify . Prior treatment endocrine therapy adjuvant metastatic setting permit provided therapy discontinue . Prior treatment radiation therapy palliative management nontarget lesion metastatic disease permit provide least 2 week elapse since last fraction radiation therapy , disease progression document treatment related adverse event ≦ grade 1 time registration . Life expectancy ≥ 12 week ECOG performance status 01 Patients must normal organ marrow function measure within 14 day prior study entry define : WBC ≥ 3,000/mm3 Absolute neutrophil count ≥ 1,500/mm3 Platelet count ≥ 100,000/mm3 Bilirubin normal AST/ALT ≤ 2.5 time upper limit normal Normal serum creatinine OR creatinine clearance ≥60 mL/min LVEF ≥ 50 % ( MUGA ) Negative pregnancy test Fertile patient must use effective contraception Able swallow retain medication No history allergic reaction attribute compound similar chemical biologic composition lapatinib Patient consent must obtain . Pregnant lactating woman . Subjects current active hepatic biliary disease ( exception patient Gilbert 's syndrome , asymptomatic gallstone , liver metastasis stable chronic liver disease per investigator assessment ) Prior therapy concurrent use Lapatinib . CNS metastasis . Ongoing concurrent investigational agent anticancer therapy Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , uncontrolled hypertension , unstable angina pectoris , cardiac arrhythmia , serious nonhealing wound/ulcer/bone fracture , psychiatric illness/social situation would limit compliance study requirement . Patients GI tract disease result inability take medication , malabsorption syndrome , requirement IV alimentation , prior surgical procedure affect absorption , uncontrolled inflammatory GI disease ( e.g. , Crohn 's , ulcerative colitis ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>ErbB receptor</keyword>
	<keyword>tyrosine kinase inhibitor</keyword>
	<keyword>Anthracycline</keyword>
</DOC>